{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:30:25Z","timestamp":1776497425208,"version":"3.51.2"},"reference-count":164,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cardiotoxic therapies, whether chemotherapeutic or antibiotic, represent a burden for patients who may need to interrupt life-saving treatment because of serious complications. Cardiotoxicity is a broad term, spanning from forms of heart failure induction, particularly left ventricular systolic dysfunction, to induction of arrhythmias. Nanotechnologies emerged decades ago. They offer the possibility to modify the profiles of potentially toxic drugs and to abolish off-target side effects thanks to more favorable pharmacokinetics and dynamics. This relatively modern science encompasses nanocarriers (e.g., liposomes, niosomes, and dendrimers) and other delivery systems applicable to real-life clinical settings. We here review selected applications of nanotechnology to the fields of pharmacology and cardio-oncology. Heart tissue-sparing co-administration of nanocarriers bound to chemotherapeutics (such as anthracyclines and platinum agents) are discussed based on recent studies. Nanotechnology applications supporting the administration of potentially cardiotoxic oncological target therapies, antibiotics (especially macrolides and fluoroquinolones), or neuroactive agents are also summarized. The future of nanotechnologies includes studies to improve therapeutic safety and to encompass a broader range of pharmacological agents. The field merits investments and research, as testified by its exponential growth.<\/jats:p>","DOI":"10.3390\/pharmaceutics15010087","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T08:42:22Z","timestamp":1672216942000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Myocardial Cell Preservation from Potential Cardiotoxic Drugs: The Role of Nanotechnologies"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3208-4689","authenticated-orcid":false,"given":"Adelaide","family":"Iervolino","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-4121","authenticated-orcid":false,"given":"Luigi","family":"Spadafora","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00189 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano","family":"Spadaccio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Iervolino","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire Henri-Mondor, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Paris Est Cr\u00e9teil, 94000 Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6103-8510","authenticated-orcid":false,"given":"Giuseppe","family":"Biondi Zoccai","sequence":"additional","affiliation":[{"name":"Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00189 Rome, Italy"},{"name":"Mediterranea Cardiocentro, 80122 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1456-6430","authenticated-orcid":false,"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An \u00f9International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2021","journal-title":"Eur. Hear. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Hear. J."},{"key":"ref_3","first-page":"1","article-title":"Emerging Theranostics to Combat Cancer: A Perspective on Metal Based Nanomaterials","volume":"30","author":"Agnihotri","year":"2022","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113043","DOI":"10.1016\/j.colsurfb.2022.113043","article-title":"Nanotechnology as a tool to overcome macromolecules delivery issues","volume":"222","author":"Tundisi","year":"2022","journal-title":"Colloids Surf B Biointerfaces."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"213147","DOI":"10.1016\/j.bioadv.2022.213147","article-title":"Theranostic magnetic nanoparticles enhance DNA damage and mitigate doxorubicin-induced cardio-toxicity for effective multi-modal tumor therapy","volume":"142","author":"Shetake","year":"2022","journal-title":"Biomater. Adv."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kumar, L., Verma, S., Utreja, P., and Kumar, D. (2022). Overview of inorganic nanoparticles: An expanding horizon in tumor therapeutics. Recent Pat Anticancer. Drug Discov.","DOI":"10.2174\/1574892817666221005094423"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.actbio.2021.06.016","article-title":"Dual targeting smart drug delivery system for multimodal synergistic combination cancer therapy with reduced cardiotoxicity","volume":"131","author":"Shubhra","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3892\/br.2021.1418","article-title":"Nanotechnology and its use in imaging and drug delivery (Review)","volume":"14","author":"Sim","year":"2021","journal-title":"Biomed. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bayda, S., Adeel, M., Tuccinardi, T., Cordani, M., and Rizzolio, F. (2020). The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine. Molecules, 25.","DOI":"10.3390\/molecules25010112"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13205-014-0214-0","article-title":"Nanoemulsion: An advanced mode of drug delivery system","volume":"5","author":"Jaiswal","year":"2015","journal-title":"3 Biotech"},{"key":"ref_12","first-page":"38","article-title":"Strategic use of nanotechnology in drug targeting and its consequences on human health: A focused review","volume":"11","author":"Maurya","year":"2019","journal-title":"Interv. Med. Appl. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.colsurfb.2012.06.024","article-title":"Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats","volume":"101","author":"Khalil","year":"2013","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1567201817666200708113131","article-title":"Liposomes for Enhanced Cellular Uptake of Anticancer Agents","volume":"17","author":"Arafa","year":"2020","journal-title":"Curr. Drug Deliv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1039\/D1TB00126D","article-title":"Liposomes for oral delivery of protein and peptide-based therapeutics: Challenges, formulation strategies, and advances","volume":"9","author":"Jash","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113642","DOI":"10.1016\/j.jpba.2020.113642","article-title":"Analytical characterization of liposomes and other lipid nanoparticles for drug delivery","volume":"192","author":"Fan","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control Release"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","article-title":"Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer","volume":"30","author":"Malam","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"Biodrugs"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Cipolla, D., Blanchard, J., Gonda, I., Cipolla, D., Blanchard, J., and Gonda, I. (2016). Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics, 8.","DOI":"10.3390\/pharmaceutics8010006"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.4103\/0110-5558.76435","article-title":"Niosome: A future of targeted drug delivery systems","volume":"1","author":"Kazi","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1248\/bpb.34.945","article-title":"Niosomes: A controlled and novel drug delivery system","volume":"34","author":"Rajera","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112298","DOI":"10.1016\/j.colsurfb.2021.112298","article-title":"Predicting the packing parameter for lipids in monolayers with the use of molecular dynamics","volume":"211","author":"Kobierski","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3329\/dujps.v14i1.23744","article-title":"Rifampicin niosome: Preparations, characterizations and antibacterial activity against staphylococcus aureus and staphylococcus epidermidis isolated from acne","volume":"14","author":"Begum","year":"2015","journal-title":"Dhaka Univ. J. Pharm. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2012.09.018","article-title":"Anti-inflammatory activity of novel ammonium glycyrrhizinate\/niosomes delivery system: Human and murine models","volume":"164","author":"Marianecci","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chauhan, A.S. (2018). Dendrimers for Drug Delivery. Molecules, 23.","DOI":"10.3390\/molecules23040938"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: Synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4155\/tde-2017-0091","article-title":"Dendritic polymers for dermal drug delivery","volume":"8","author":"Dave","year":"2017","journal-title":"Ther. Deliv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1158\/1538-7445.AM2020-1716","article-title":"Abstract 1716: Anticancer activity of the taxane nanoparticles, DEP\u00ae docetaxel and DEP\u00aecabazitaxel","volume":"80","author":"Kelly","year":"2020","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cplett.2010.04.067","article-title":"Progress and Challenges for the Bottom-Up Synthesis of Carbon Nanotubes with Discrete Chirality","volume":"494","author":"Jasti","year":"2010","journal-title":"Chem. Phys. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s11671-016-1730-0","article-title":"Can We Optimize Arc Discharge and Laser Ablation for Well-Controlled Carbon Nanotube Synthesis?","volume":"11","author":"Das","year":"2016","journal-title":"Nanoscale Res. Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.msec.2018.07.012","article-title":"Carbon nanoparticles suspension injection for the delivery of doxorubicin: Comparable efficacy and reduced toxicity","volume":"92","author":"Huang","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1166\/jnn.2014.8765","article-title":"Doxorubicin nanoconjugates","volume":"14","author":"Deepa","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"954470","DOI":"10.3389\/fbioe.2022.954470","article-title":"Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics","volume":"10","author":"Zhang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"120252","DOI":"10.1016\/j.biomaterials.2020.120252","article-title":"Effective treatment of drug-resistant lung cancer via a nanogel capable of reactivating cisplatin and enhancing early apoptosis","volume":"257","author":"Sun","year":"2020","journal-title":"Biomaterials"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2019.01.040","article-title":"Saporin-loaded CD44 and EGFR dual-targeted nanogels for potent inhibition of metastatic breast cancer in vivo","volume":"560","author":"Chen","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ghaffari, M. (2019). Industrial Applications of Nanomaterials. Nanotechnol. Pharm., 475\u2013502.","DOI":"10.1016\/B978-0-12-815749-7.00017-7"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s42247-021-00335-x","article-title":"Review on metal nanoparticles as nanocarriers: Current challenges and perspectives in drug delivery systems","volume":"5","author":"Chandrakala","year":"2022","journal-title":"Emergent Mater."},{"key":"ref_41","unstructured":"NIH US National US Library of Medicine (2022, October 10). Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate: A Phase 0 Study in Men (MAGNABLATE I). ClinicalTrials.gov Identifier: NCT02033447, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02033447."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Figueiredo, A.Q., Rodrigues, C.F., Fernandes, N., de Melo-Diogo, D., Correia, I.J., and Moreira, A.F. (2022). Metal-Polymer Nanoconjugates Application in Cancer Imaging and Therapy. Nanomaterials, 12.","DOI":"10.3390\/nano12183166"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/macromol2030024","article-title":"Magnetic Nanoparticles for Medical Applications: Updated Review","volume":"2","author":"Mendizabal","year":"2022","journal-title":"Macromol"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Dias, A.M.M., Courteau, A., Bellaye, P.-S., Kohli, E., Oudot, A., Doulain, P.-E., Petitot, C., Walker, P.-M., Decr\u00e9au, R., and Collin, B. (2022). Superparamagnetic Iron Oxide Nanoparticles for Immunotherapy of Cancers through Macrophages and Magnetic Hyperthermia. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112388"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12668-022-00947-5","article-title":"Synthesis and Stability of Magnetic Nanoparticles","volume":"12","author":"Ansari","year":"2022","journal-title":"BionanoScience"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2217\/nnm-2021-0348","article-title":"A review of recent advances in magnetic nanoparticle-based theranostics of glioblastoma","volume":"17","author":"Dhar","year":"2022","journal-title":"Nanomedicine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Liu, X., Wang, N., Liu, X., Deng, R., Kang, R., and Xie, L. (2022). Vascular Repair by Grafting Based on Magnetic Nanoparticles. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071433"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"23737","DOI":"10.1021\/acsami.0c05308","article-title":"Magnetic targeting and ultrasound activation of liposome-microbubble conjugate for enhanced delivery of anticancer therapies","volume":"12","author":"Dwivedi","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"121056","DOI":"10.1016\/j.biomaterials.2021.121056","article-title":"Designer exosomes enabling tumor targeted efficient chemo\/gene\/photothermal therapy","volume":"276","author":"Wang","year":"2021","journal-title":"Biomaterials"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcis.2022.11.151","article-title":"Biointerfacial giant capsules with high paclitaxel loading and magnetic targeting for breast tumor therapy","volume":"633","author":"Tan","year":"2022","journal-title":"J. Colloid Interface Sci."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Zimina, T.M., Sitkov, N.O., Gareev, K.G., Fedorov, V., Grouzdev, D., Koziaeva, V., Gao, H., Combs, S.E., and Shevtsov, M. (2022). Biosensors and Drug Delivery in Oncotheranostics Using Inorganic Synthetic and Biogenic Magnetic Nanoparticles. Biosensors, 12.","DOI":"10.3390\/bios12100789"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.2174\/1871520618666180313154724","article-title":"Co-delivery of Doxorubicin and D-\u03b1-Tocopherol Polyethylene Glycol 1000 Succinate by Magnetic Nanoparticles","volume":"18","author":"Metin","year":"2018","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1021\/mp200522d","article-title":"Doxorubicin-Conjugated PEGylated Dendrimers Show Similar Tumoricidal Activity but Lower Systemic Toxicity When Compared to PEGylated Liposome and Solution Formulations in Mouse and Rat Tumor Models","volume":"9","author":"Kaminskas","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Alavi, M., and Hamidi, M. (2019). Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab. Pers. Ther., 34.","DOI":"10.1515\/dmpt-2018-0032"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.canlet.2012.07.002","article-title":"Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer","volume":"334","author":"Yang","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cmdc.202000131","article-title":"Antitumour Anthracyclines: Progress and Perspectives","volume":"15","author":"Carvalho","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_58","unstructured":"Venkatesh, P., and Kasi, A. (2022). Anthracyclines. StatPearls, StatPearls Publishing."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"Sawyer","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1021\/acs.nanolett.9b01202","article-title":"Quantitative Drug Release Monitoring in Tumors of Living Subjects by Magnetic Particle Imaging Nanocomposite","volume":"19","author":"Zhu","year":"2019","journal-title":"Nano Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phrs.2010.03.005","article-title":"Targeting nanoparticles to cancer","volume":"62","author":"Wang","year":"2010","journal-title":"Pharmacol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejps.2018.05.004","article-title":"How to measure release from nanosized carriers?","volume":"120","author":"Nothnagel","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"898146","DOI":"10.1155\/2013\/898146","article-title":"Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer","volume":"2013","author":"Pisano","year":"2013","journal-title":"J. Drug Deliv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1177\/0960327120930266","article-title":"Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice","volume":"39","author":"Badawy","year":"2020","journal-title":"um. Exp. Toxicol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejps.2015.12.031","article-title":"Recent advances in polymeric micelles for anti-cancer drug delivery","volume":"83","author":"Biswas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jconrel.2017.04.039","article-title":"Assembly of polymer micelles through the sol-gel transition for effective cancer therapy","volume":"255","author":"Khaliq","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Teixeira, M.C., Lameirinhas, N.S., Carvalho, J.P.F., Silvestre, A.J.D., Vilela, C., and Freire, C.S.R. (2022). A Guide to Polysaccharide-Based Hydrogel Bioinks for 3D Bioprinting Applications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126564"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2015.06.040","article-title":"Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo","volume":"213","author":"Cote","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The sideeffects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.resp.2013.03.013","article-title":"Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients","volume":"187","author":"Demkow","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/13543780903114168","article-title":"Clinical overview on Lipoplatin: A successful liposomal formulation of cisplatin","volume":"18","author":"Boulikas","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_75","first-page":"1","article-title":"Reducing the effective dose of cisplatin using gold nanoparticles as carriers","volume":"11","year":"2020","journal-title":"Cancer Nanotechnol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.2147\/IJN.S247114","article-title":"Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer","volume":"15","author":"Bortot","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/10717544.2019.1642420","article-title":"Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin","volume":"26","author":"Khan","year":"2019","journal-title":"Drug Deliv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"115333","DOI":"10.1016\/j.carbpol.2019.115333","article-title":"Synthesis of chitosan-grafted-poly(N-vinylcaprolactam) coated on the thiolated gold nanoparticles surface for controlled release of cisplatin","volume":"227","author":"Banihashem","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41598-021-04427-w","article-title":"Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer","volume":"12","author":"Sultan","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12012-021-09636-3","article-title":"The Effect of Curcumin Nanoparticles on Cisplatin-Induced Cardiotoxicity in Male Wistar Albino Rats","volume":"21","author":"Khadrawy","year":"2021","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2324709613480346","DOI":"10.1177\/2324709613480346","article-title":"Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management","volume":"1","author":"Dhesi","year":"2013","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.2174\/1381612822666160211141918","article-title":"Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model","volume":"22","author":"Tiash","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Khodabakhsh, F., Bourbour, M., Yaraki, M.T., Bazzazan, S., Bakhshandeh, H., Ahangari Cohan, R., and Tan, Y.N. (2022). pH-Responsive PEGylated Niosomal Nanoparticles as an Active-Targeting Cyclophosphamide Delivery System for Gastric Cancer Therapy. Molecules, 27.","DOI":"10.3390\/molecules27175418"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"npj Precis. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/nnm.09.105","article-title":"Conjugation of Bevacizumab to Cationic Liposomes Enhances Their Tumor-Targeting Potential","volume":"5","author":"Kuesters","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled Release of Bevacizumab through Nanospheres for Extended Treatment of Age-Related Macular Degeneration","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_89","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not pertuzumab. dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/IJN.S152742","article-title":"Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles","volume":"13","author":"Colzani","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Dziawer, \u0141., Majkowska-Pilip, A., Gawe\u0142, D., Godlewska, M., Pruszy\u0144ski, M., Jastrz\u0119bski, J., W\u0105s, B., and Bilewicz, A. (2019). Trastuzumab-Modified Gold Nanoparticles Labeled with 211At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer. Nanomaterials, 9.","DOI":"10.3390\/nano9040632"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Lenz, K.D., Klosterman, K.E., Mukundan, H., and Kubicek-Sutherland, J.Z. (2021). Macrolides: From Toxins to Therapeutics. Toxins, 13.","DOI":"10.3390\/toxins13050347"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/00498254.2015.1046975","article-title":"Toxicity of macrolide antibiotics on isolated heart mitochondria: A justification for their cardiotoxic adverse effect","volume":"46","author":"Salimi","year":"2016","journal-title":"Xenobiotica"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMp078032","article-title":"The FDA and the case of Ketek","volume":"356","author":"Ross","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"16596","DOI":"10.1038\/s41598-020-73593-0","article-title":"Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction","volume":"10","author":"Donahue","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/jac\/49.4.593","article-title":"Cardiotoxicity of fluoroquinolones","volume":"49","author":"Rubinstein","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1592\/phco.21.20.1468.34482","article-title":"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin","volume":"21","author":"Frothingham","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jac\/46.5.847","article-title":"Quinolone-induced QT interval prolongation: A not-so-unexpected class effect","volume":"46","author":"Kahn","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-L\u00f3pez, M., Fern\u00e1ndez-Delgado, A., Moy\u00e1, M.L., Blanco-Ar\u00e9valo, D., Carrera, C., de la Haba, R.R., Ventosa, A., Bernal, E., and L\u00f3pez-Cornejo, P. (2019). Optimized Preparation of Levofloxacin Loaded Polymeric Nanoparticles. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11020057"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"118578","DOI":"10.1016\/j.ijpharm.2019.118578","article-title":"In vitro antibacterial activity of ciprofloxacin loaded chitosan microparticles and their effects on human lung epithelial cells","volume":"569","author":"Kucukoglu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dkt252","article-title":"Chitosan-dextran sulphate nanocapsule drug delivery system as an effective therapeutic against intraphagosomal pathogen Salmonella","volume":"68","author":"Gnanadhas","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1586\/eri.12.136","article-title":"Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa","volume":"10","author":"Antoniu","year":"2012","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"g6196","DOI":"10.1136\/bmj.g6196","article-title":"Cotrimoxazole and sudden death in patients receiving inhibitors of reninangiotensin system: Population based study","volume":"349","author":"Fralick","year":"2014","journal-title":"BMJ"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Gbian, D.L., and Omri, A. (2022). Lipid-Based Drug Delivery Systems for Diseases Managements. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092137"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s11095-022-03286-y","article-title":"Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications","volume":"39","author":"Kumar","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_107","first-page":"131","article-title":"Inhalation drug delivery devices: Technology update","volume":"8","author":"Ibrahim","year":"2015","journal-title":"Med. Devices"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled Liposomal Antimicrobial Delivery in Lung Infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","article-title":"Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients","volume":"77","author":"Drew","year":"2004","journal-title":"Transplantation"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","article-title":"Aerosolized Delivery of Antifungal Agents","volume":"4","author":"Le","year":"2010","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mmcr.2016.10.001","article-title":"Reversible cardiomyopathy secondary to Amphotericin-B","volume":"13","author":"Bandeira","year":"2016","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"bcr2013202688","DOI":"10.1136\/bcr-2013-202688","article-title":"Atrioventricular block related to liposomal amphotericin B","volume":"2014","author":"Sanches","year":"2014","journal-title":"BMJ Case Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"100216","DOI":"10.1016\/j.xcrm.2021.100216","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jacc.2018.03.458","article-title":"Psychopharmacology and Cardiovascular Disease","volume":"71","author":"Pina","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"736","DOI":"10.5498\/wjp.v11.i10.736","article-title":"Antipsychotics cardiotoxicity: What\u2019s known and what\u2019s next","volume":"11","author":"Li","year":"2021","journal-title":"World J. Psychiatry"},{"key":"ref_116","first-page":"295","article-title":"Antidepressants and cardiovascular adverse events: A narrative review","volume":"11","author":"Nezafati","year":"2015","journal-title":"ARYA Atheroscler."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/0960327115595683","article-title":"Cellular mechanisms for trazodone-induced cardiotoxicity","volume":"35","author":"Lee","year":"2016","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_118","unstructured":"Bruggeman, C., and O\u2019Day, C.S. (2022). Selective Serotonin Reuptake Inhibitor Toxicity, StatPearls."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jacc.2017.05.014","article-title":"The Cardiovascular Effects of Cocaine","volume":"70","author":"Havakuk","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"756866","DOI":"10.3389\/fmed.2021.756866","article-title":"Mechanisms and Efficacy of Intravenous Lipid Emulsion Treatment for Systemic Toxicity from Local Anesthetics","volume":"8","author":"Liu","year":"2021","journal-title":"Front. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e1695","DOI":"10.1002\/wnan.1695","article-title":"Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases","volume":"13","author":"Zhou","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Hersh, A.M., Alomari, S., and Tyler, B.M. (2022). Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int J Mol Sci., 23.","DOI":"10.3390\/ijms23084153"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1602\/neurorx.2.1.1","article-title":"The blood-brain barrier and neurotherapeutics","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRX"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.xphs.2017.04.080","article-title":"Routes for Drug Translocation Across the Blood-Brain Barrier: Exploiting Peptides as Delivery Vectors","volume":"106","author":"Kristensen","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Ruiz-L\u00f3pez, E., and Schuhmacher, A.J. (2021). Transportation of Single-Domain Antibodies through the Blood\u2013Brain Barrier. Biomolecules, 11.","DOI":"10.3390\/biom11081131"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.acvd.2013.02.003","article-title":"Drug-induced valvular heart disease: An update","volume":"106","author":"Andrejak","year":"2013","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_127","unstructured":"Singh, S., and Preuss, C.V. (2022, October 22). Carvedilol. [Updated 22 September 2022]. Treasure Island (FL). StatPearls Publishing, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534868\/."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Kourek, C., Touloupaki, M., Rempakos, A., Loritis, K., Tsougkos, E., Paraskevaidis, I., and Briasoulis, A. (2022). Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9080259"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","article-title":"Preventive role of carvedilol in adriamycin-induced cardiomyopathy","volume":"144","author":"Jhorawat","year":"2016","journal-title":"Indian J. Med Res."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: Insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur. Hear. J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/164_2016_77","article-title":"Sacubitril\/Valsartan (LCZ696) in Heart Failure","volume":"243","author":"Khder","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Scott","year":"2005","journal-title":"Drugs"},{"key":"ref_133","unstructured":"US Food and Drug Administration (2022, October 10). Orphan Drug Designations and Approvals, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=441314."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00108-021-01083-0","article-title":"Gliflozine-in Zukunft Kardioprotektiva? [Gliflozins-in future cardioprotective drugs?]","volume":"62","author":"Landmesser","year":"2021","journal-title":"Internist"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1093\/eurheartj\/suab094","article-title":"Surprises in cardiology: Efficacy of gliflozines in heart failure even in the absence of diabetes","volume":"23","author":"Bragagni","year":"2021","journal-title":"Eur. Hear. J. Suppl."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/21655979.2021.2012907","article-title":"New challenges in the use of nanomedicine in cancer therapy","volume":"13","author":"Rasool","year":"2022","journal-title":"Bioengineered"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Yadav, A.B., Swaroop, S., Bechelany, M., and Barhoum, A. (2022). Review on Nanoparticles and Nanostructured Materials: Bioimaging, Biosensing, Drug Delivery, Tissue Engineering, Antimicrobial, and Agro-Food Applications. Nanomaterials, 12.","DOI":"10.3390\/nano12030457"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Nicosia, A., Cavallaro, G., Costa, S., Utzeri, M.A., Cuttitta, A., Giammona, G., and Mauro, N. (2020). Carbon Nanodots for On Demand Chemophotothermal Therapy Combination to Elicit Necroptosis: Overcoming Apoptosis Resistance in Breast Cancer Cell Lines. Cancers, 12.","DOI":"10.3390\/cancers12113114"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tiv.2009.09.007","article-title":"Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles","volume":"24","author":"Huang","year":"2010","journal-title":"Toxicol. Vitr."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.tiv.2009.08.005","article-title":"Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells","volume":"23","author":"Fahmy","year":"2009","journal-title":"Toxicol. Vitr."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.toxlet.2009.03.014","article-title":"Size-dependent toxicity of metal oxide particles--a comparison between nano- and micrometer size","volume":"188","author":"Karlsson","year":"2009","journal-title":"Toxicol. Lett."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"104690","DOI":"10.1016\/j.yrtph.2020.104690","article-title":"Pulmonary toxicity of silver vapours, nanoparticles and fine dusts: A review","volume":"115","author":"Hadrup","year":"2020","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/jps.24001","article-title":"Silver nanoparticles: Therapeutical uses, toxicity, and safety issues","volume":"103","author":"Seckler","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"690533","DOI":"10.3389\/fcvm.2021.690533","article-title":"Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies","volume":"8","author":"Borges","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: Evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2015.08.068","article-title":"Preclinical mouse cancer models: A maze of opportunities and challenges","volume":"163","author":"Day","year":"2015","journal-title":"Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.colsurfb.2019.04.030","article-title":"Nanotechnology-based formulations for resveratrol delivery: Effects on resveratrol in vivo bioavailability and bioactivity","volume":"180","author":"Santos","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1124\/mi.6.1.7","article-title":"Resveratrol in cardioprotection: A therapeutic promise of alternative medicine","volume":"6","author":"Das","year":"2006","journal-title":"Mol. Interv."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Ko, J.H., Sethi, G., Um, J.Y., Shanmugam, M.K., Arfuso, F., Kumar, A.P., Bishayee, A., and Ahn, K.S. (2017). The Role of Resveratrol in Cancer Therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122589"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Khattar, S., Khan, S.A., Zaidi, S.A.A., Darvishikolour, M., Farooq, U., Naseef, P.P., Kurunian, M.S., Khan, M.Z., Shamim, A., and Khan, M.M.U. (2022). Resveratrol from Dietary Supplement to a Drug Candidate: An Assessment of Potential. Pharmaceuticals, 15.","DOI":"10.3390\/ph15080957"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijpharm.2015.01.003","article-title":"Resveratrol nanoformulations: Challenges and opportunities","volume":"479","author":"Summerlin","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.03.016","article-title":"Cardioprotective microRNAs: Lessons from stem cell-derived exosomal microRNAs to treat cardiovascular disease","volume":"285","author":"Moghaddam","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1413534","article-title":"Remote ischemic preconditioning and outcomes of cardiac surgery","volume":"373","author":"Hausenloy","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/aas.13296","article-title":"Remote ischaemic preconditioning increases serum extracellular vesicle concentrations with altered micro\u2212RNA signature in CABG patients","volume":"63","author":"Frey","year":"2018","journal-title":"Acta Anaesthesiol. Scand."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Brevoord, D., Kranke, P., Kuijpers, M., Weber, N., Hollmann, M., and Preckel, B. (2012). Remote ischemic conditioning to protect against ischemia-reperfusion injury: A systematic review and meta-analysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042179"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1161\/CIRCRESAHA.110.236190","article-title":"Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction","volume":"108","author":"Wei","year":"2011","journal-title":"Circ. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fbioe.2020.00149","article-title":"MicroRNA Mediated Cardioprotection\u2014Is There a Path to Clinical Translation?","volume":"8","author":"Exarchos","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/biof.1823","article-title":"The cardioprotective effects of nano-curcumin against doxorubicin-induced cardiotoxicity: A systematic review","volume":"48","author":"Moutabian","year":"2022","journal-title":"Biofactors"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ptr.7283","article-title":"Quercetin and its role in modulating endoplasmic reticulum stress: A review","volume":"36","author":"Eisvand","year":"2022","journal-title":"Phytother. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1080\/10408398.2021.1875979","article-title":"Hesperetin\u2019s health potential: Moving from preclinical to clinical evidence and bioavailability issues, to upcoming strategies to overcome current limitations","volume":"62","author":"Salehi","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"571482","DOI":"10.3389\/fphar.2021.571482","article-title":"Curcumin Nanoparticles Attenuate Lipotoxic Injury in Cardiomyocytes Through Autophagy and Endoplasmic Reticulum Stress Signaling Pathways","volume":"12","author":"Gu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1039\/D0BM01335H","article-title":"Nanobody-displaying porous silicon nanoparticles for the co-delivery of siRNA and doxorubicin","volume":"9","author":"Tieu","year":"2021","journal-title":"Biomater. Sci."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Toro-C\u00f3rdova, A., Llaguno-Munive, M., Jurado, R., and Garcia-Lopez, P. (2022). The Therapeutic Potential of Chemo\/Thermotherapy with Magnetoliposomes for Cancer Treatment. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112443"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2217\/nnm.11.79","article-title":"In vivo biodistribution of nanoparticles","volume":"6","author":"Almeida","year":"2011","journal-title":"Nanomedicine"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:52:43Z","timestamp":1760147563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":164,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["pharmaceutics15010087"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15010087","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]}}}